Eli Lilly breaks ground on US$3.5B obesity drug manufacturing facility in Pennsylvania

The Lehigh Valley facility is expected to become operational by 2031.

USA—Eli Lilly and Company has broken ground on a US$3.5 billion manufacturing facility in Fogelsville, Pennsylvania, to expand domestic production of injectable medicines and support its next generation of obesity treatments, including the investigational drug retatrutide.

The facility is part of Lilly’s US$50 billion investment in expanding US medicine manufacturing and is one of 10 new sites announced since 2020.

Four of these facilities are dedicated to injectable medicines and medical devices, reflecting the company’s efforts to increase production capacity as demand for advanced treatments grows.

Retatrutide is an investigational triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon pathways.

The medicine is being developed for people living with obesity, type 2 diabetes or both.

Lilly Chair and CEO David A. Ricks said the investment would strengthen the company’s ability to manufacture next-generation obesity treatments for patients in the US and international markets.

He noted that advances in obesity research are creating opportunities to expand treatment options for millions of people.

Facility to create jobs and strengthen local healthcare initiatives

The project is expected to create 850 permanent, high-paying jobs for engineers, scientists, manufacturing personnel and laboratory technicians.

Construction is also expected to generate approximately 2,000 jobs as the facility is developed and commissioned.  

Lilly has begun recruiting for positions at the site.

Alongside the investment, Lilly will provide up to US$1 million over five years to the Upper Macungie Township Community Fund to support a community health initiative at the Upper Macungie Community Center.

The programme will focus on nutrition, healthy living, access to fresh food, health resources and community activities.

Advanced manufacturing and quality control

The facility will incorporate machine learning, artificial intelligence (AI), digital integration and advanced data analytics to improve manufacturing efficiency and quality control.

Digital automation will be embedded across operations to support consistent production and reduce errors.

Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations, said each medicine production run undergoes more than 5,000 documented steps, while individual units are imaged and inspected more than 70 times before release.

He noted that the Pennsylvania facility would build on these quality assurance processes through advanced automation and digital systems.

The company is targeting Leadership in Energy and Environmental Design (LEED) Gold certification for the facility, reflecting its commitment to energy efficiency and environmental management.

Pennsylvania Governor Josh Shapiro said the investment would strengthen the state’s life sciences industry, expand its manufacturing base and create skilled employment opportunities.

US Senator Dave McCormick also highlighted the project’s contribution to domestic manufacturing and economic growth.

Lilly has announced 10 US manufacturing sites since 2020.

Five will produce active pharmaceutical ingredients, including facilities in Richmond, Virginia; Huntsville, Alabama; Houston, Texas; and two locations in Lebanon, Indiana.

Four will manufacture injectable medicines and devices in North Carolina, Wisconsin and Pennsylvania, while the Lebanon Advanced Therapies facility will focus on genetic medicines.

The Lehigh Valley facility is expected to become operational by 2031.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.

Visited 13 times, 13 visit(s) today

Newer Post

Thumbnail for Eli Lilly breaks ground on US$3.5B obesity drug manufacturing facility in Pennsylvania

Valeo Health launches UNLOCK longevity programme in UAE to advance preventive healthcare

Older Post

Thumbnail for Eli Lilly breaks ground on US$3.5B obesity drug manufacturing facility in Pennsylvania

Mayo Clinic maps deep brain region to improve epilepsy stimulation targeting

Be the first to leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *